However, despite its mechanistic rationale, arimoclomol failed to provide meaningful clinical benefit in ALS patients and was associated with adverse effects, including an increase in NfL levels of approximately 29% compared with placebo [45], which is in sharp contrast to the reduction in NfL observed after CBIT2. Here, NEFL is linked to amyotrophic lateral sclerosis.